Ascendis Pharma A/S To Report Full Year 2014 Financial Results And Host Conference Call On March 25, 2015

COPENHAGEN, Denmark, March 18, 2015 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced that the company will host a conference call on Wednesday, March 25, 2015, at 4:30 p.m. Eastern Time to discuss its Full Year 2014 financial results. The conference call will follow the release of the Ascendis Pharma Full Year 2014 financial results after the close of market that day.

Ascendis Pharma logo

Conference Call Information 
          Date: Wednesday, March 25, 2015
          Time: 4:30 p.m. ET
          Dial-in (United States): (866) 682-8490
          Dial-in (International): +44 (0) 1452 555131

A simultaneous webcast of the conference call will be available on the Investor Relations tab of the Ascendis Pharma website at A replay of this webcast will be available on the website shortly after the conclusion of the call and will be available through April 30, 2015.

About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained release technologies, to develop a pipeline of best-in-class therapeutics that address significant unmet medical needs.  The TransCon technology can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug.   

The Ascendis Pharma pipeline includes TransCon Growth Hormone, a proprietary program that has completed a Phase 2 study in adults with growth hormone deficiency, or GHD.  Ascendis Pharma is currently conducting a Phase 2 study of TransCon Growth Hormone in children with GHD.  Ascendis Pharma is also developing its wholly-owned TransCon Treprostinil for the treatment of pulmonary arterial hypertension, or PAH.  TransCon Treprostinil is currently in a Phase 1 single ascending dose study in healthy volunteers.  In addition to its proprietary programs, Ascendis Pharma has formed collaborations focused on leading products in large markets that are of strategic importance to its collaboration partners.  These collaborations are with Sanofi in diabetes and Genentech in the field of ophthalmology.


Investor contact:
Martin Auster, M.D.
Chief Business Officer
(650) 617-3403           

Logo -


To view the original version on PR Newswire, visit:

SOURCE Ascendis Pharma A/S

Help employers find you! Check out all the jobs and post your resume.

Back to news